Displaying items by tag: hiv aids

Join us at the Alabama Vaccine Research Clinic at UAB! We are looking for volunteers to join a Phase 1 clinical trial to test the safety and immune response of a new HIV vaccine. The study is for adults who are HIV-negative, in good health, and aged 18 to 55. Procedures will include blood draws and injections of the study vaccine, as well as the collection of white blood cells through a procedure called leukapheresis. Participants will be compensated for their time in this study. The study vaccine will not give you HIV. If you are interested, please call 205-934-6777 or email avrc@uabmc.edu. You can also fill out our contact form at https://sites.uab.edu/avrc/contact-us/.
Published in Clinical Trials
Study Information:
  • Are you 18-60 years of age living with HIV, and want to be a part of a vaccine study?
  • Is your viral load suppressed/undetectable?
  • Are you able to receive a vaccine?
  • Are you generally healthy?
  • Are you willing to temporarily stop taking antiretrovirals?

You may qualify for a study looking at testing an experimental HIV vaccine with an experimental adjuvant to see how the immune responses change among participants who do an antiretroviral analytical treatment interruption (ATI) compared to those who do not. Compensation at each study visit will be provided for time and travel. Transportation services are also available upon request. If interested, please email sspaulding@uabmc.edu.

Published in Clinical Trials
• Are you 18-70 years of age living with HIV, and want to be a part of a curative study?
• Is your viral load suppressed/undetectable?
• Are you able to receive an infusion or injection?
• Are you generally healthy?
• Are you willing to temporarily stop taking antiretrovirals?

You may qualify for a HIV treatment study looking at an investigational way to effectively clear the HIV virus in areas of the body that standard antiretroviral treatment is unable to reach. You will receive one of two potential intervention methods. One intervention method is a broadly neutralizing antibody that is given to control growth of the HIV virus and to increase the body’s immune system response. The second intervention method is an injection (IL-15 Superagonist) designed to awaken the immune system, activate any dormant HIV virus, and then kill the virus. The duration of this study is approximately 84-112 weeks pending on which intervention method you receive. There is compensation at each study visit for time and travel.


Contact: If interested, please email kspraggins@uabmc.edu or call 205-934-9346
Published in Clinical Trials
Are you:
• A woman on parole, probation, or recently released from prison or jail?
• A woman who has used drugs?
• Interested in learning about a way to protect yourself against HIV?

You may qualify for a paid research study at the University of Alabama at Birmingham, in partnership with Yale University.
• Participate in confidential study interviews at our research office.
• Earn $50 for each interview, up to $225 for participating in the study.

Fill out our contact survey at: https://yalesurvey.ca1.qualtrics.com/jfe/form/SV_d7sAjr6GDsjiJng?Q_CHL=qr

Or you may call: (205) 934-2851 or Email: AthenaStudy@uabmc.edu
Published in Clinical Trials
This study will examine predictors of successful aging outcomes among adults and older adults with and without HIV. We are currently recruiting HIV-negative controls, thus to qualify, you must be HIV-negative, age 50 or older, be proficient in English, must not be mentally impaired or have significant neuromedical issues, and must consent to a blood draw. Eligible participants may be compensated up to $150 for a ~5-hour visit. For more information, please call 205-934-2862.
Published in Clinical Trials
Study examines how HIV affects the health of women.
Published in Research & Scholarship

UAB and Birmingham stepped up to fight the virus that causes AIDS years ago when it could have easily turned away

Published in Patient Care

UAB Hospital will begin screening every patient treated in the ER to reduce those numbers through a program funded by the Centers for Disease Control and Prevention.

Published in Extramural Awards